Infrared Sciences Corp., Manufacturer of the Sentinel BreastScan, a Non-Invasive Breast Cancer Detection System, is Seeking Strategic Acquirer

Share Article

Infrared Sciences Corp., manufacturer of the Sentinel BreastScan, is seeking a strategic acquirer for the possible sale of the company or the sale of the company's assets. ISC also announced that it has completed the clinical study of the Sentinel BreastScan at Cornell Weill Medical College, and the Study results were published in the American Journal of Surgery.

that the Cornell study was the only recent study conducted in a prestigious academic institution of breast cancer detection utilizing state-of-the-art digital infrared imaging, and will be a major factor in the acceptance and expansion of the Sentinel BreastScan within main-stream medicine

Infrared Sciences Corp., the manufacturer of the Sentinel BreastScan breast cancer detection system, announced today it is aggressively seeking a strategic buyer for the Company, and invites all interested parties to contact the company as soon as possible. Thomas DiCicco, ISC's President and CEO, said, "Due to the current economic climate and the general lack of investment capital, ISC was unable to secure the necessary investment funds to sustain the operation and growth of the company. This will result in the company being forced to cease operation in the next few months. In order to preserve this valuable technology, we have decided to seek a strategic acquirer for the company. ISC has all the necessary ingredients that make an excellent healthcare investment opportunity including; tremendous market need, FDA clearance and CE Mark. The Sentinel BreastScan™ is currently generating revenue, it has completed clinical studies,and has published results in a major peer review medical journal."

The Sentinel BreastScan, an adjunctive non-invasive breast cancer detection system, has undergone clinical testing at the Cornell Weill Medical College of Cornell University in New York City. The results of the study were published in the American Journal of Surgery this past October 2008. Thomas DiCicco commented that "that the results were excellent, with sensitivities approaching 97%, and reinforced the tremendous potential of this non-invasive technology". He added "that the Cornell study was the only recent study conducted in a prestigious academic institution of breast cancer detection utilizing state-of-the-art digital infrared imaging, and will be a major factor in the acceptance and expansion of the Sentinel BreastScan within main-stream medicine". The Sentinel BreastScan is unlike any other infrared system; being a fully automated dynamic test, employing artificial intelligence software, and a providing a fully interpreted real-time test report to the doctor. DiCicco added, "All women of any age stand to benefit from this technological leap forward, by providing their doctor with physiologic breast health data with a low cost, painless, non-invasive test; data that is not available from any other breast cancer test today."

Interested parties are invited to contact Mr. DiCicco as soon as possible.

About Infrared Sciences Corp.
Infrared Sciences Corp. is a New York-based technology company focused on the early detection of breast cancer. Its FDA-cleared and CE Mark approved, Sentinel BreastScan system has undergone more than 9 years of testing at several leading medical facilities. For more information contact Infrared Sciences Corporation, at 1650 Sycamore Ave. Suite 4, Bohemia, NY 11716. TEL: 631 240-9106, FAX: 631 750-3396, 516 317-9637 mobile, or visit http://www.infraredsciences.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

THOMAS DICICCO
Visit website